Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients

被引:22
作者
Kuniholm, Mark H. [1 ]
Mark, Jennifer [1 ]
Aladashvili, Malvina [2 ]
Shubladze, N. [3 ]
Khechinashvili, G. [3 ]
Tsertsvadze, Tengiz [2 ]
del Rio, Carlos [4 ]
Nelson, Kenrad E. [1 ,5 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Georgian AIDS & Clin Immunol Res Ctr, Tbilisi, Georgia
[3] Natl Ctr TB & Lung Dis, Tbilisi, Georgia
[4] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[5] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
关键词
hepatitis C; HIV; hepatitis B; tuberculosis; hepatotoxicity; Georgia; epidemiology;
D O I
10.1016/j.ijid.2007.04.015
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To determine prevalence, risk factors, and simple identification algorithms for HIV, hepatitis B, and hepatitis C co-infection; factors that may predispose for anti-tuberculosis therapy-induced hepatotoxicity. Methods: We recruited 300 individuals at in-patient tuberculosis hospitals in three cities in Georgia, administered a behavioral questionnaire, and tested for antibody to HIV, hepatitis C (HCV), hepatitis B core antigen (anti-HBc), and the hepatitis B surface antigen (HBsAg). Results: Of the individuals tested, 0.7% were HIV positive, 4.3% were HBsAg positive, 8.7% were anti-HBc positive, and 12.0% were HCV positive. In multivariable analysis, a history of blood transfusion, injection drug use, and prison were significant independent risk factors for HCV, white a history of blood transfusion, injection drug use, younger age at sexual debut, and a high number of sex partners were significant risk factors for HBV. Three-questionnaire item algorithms predicted HCV serostatus 74.1% of the time and HBV serostatus 85.2% of the time. Conclusions: Treatment of tuberculosis patients in resource-limited countries with concurrent epidemics of HCV, HBV, and HIV may be associated with significant hepatotoxicity. Serologic screening of tuberculosis patients for HBV, HCV, and HIV or using behavioral algorithms to identify patients in need of intensive monitoring during anti-tuberculosis therapy may reduce this risk. (C) 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 36 条
  • [1] Aerts A, 2000, INT J TUBERC LUNG D, V4, P1104
  • [2] Monitoring and management of antituberculosis drug induced hepatotoxicity
    Agal, S
    Baijal, R
    Pramanik, S
    Patel, N
    Gupte, P
    Kamani, P
    Amarapurkar, D
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (11) : 1745 - 1752
  • [3] Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection
    Aziz, H
    Shubair, M
    DeBari, VA
    Ismail, M
    Khan, MA
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (01) : 217 - 221
  • [4] Achieving the millennium development goals for health - Cost effectiveness analysis of strategies for tuberculosis control in developing countries
    Baltussen, R
    Floyd, K
    Dye, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7529): : 1364 - 1368
  • [5] Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors
    Butsashvili, M
    Tsertsvadze, T
    McNutt, LA
    Kamkamidze, G
    Gvetadze, R
    Badridze, N
    [J]. EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2001, 17 (07) : 693 - 695
  • [6] Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally
    Dye, C
    Watt, CJ
    Bleed, DM
    Hosseini, SM
    Raviglione, MC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (22): : 2767 - 2775
  • [7] Global epidemiology of tuberculosis
    Dye, C
    [J]. LANCET, 2006, 367 (9514) : 938 - 940
  • [8] Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country
    Dye, C
    Scheele, S
    Dolin, P
    Pathania, V
    Raviglione, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07): : 677 - 686
  • [9] Isoniazid hepatotoxicity among drug users:: The role of hepatitis C
    Fernández-Villar, A
    Sopeña, B
    Vázquez, R
    Ulloa, F
    Fluiters, E
    Mosteiro, M
    Martínez-Vázquez, C
    Piñeiro, L
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (03) : 293 - 298
  • [10] Anti-infectives - Adverse reactions to first-line antituberculosis drugs
    Forget, Eric J.
    Menzies, Dick
    [J]. EXPERT OPINION ON DRUG SAFETY, 2006, 5 (02) : 231 - 249